Glenmark Pharmaceuticals Ltd (NSE:GLENMARK)
₹ 1194.15 -15.7 (-1.3%) Market Cap: 336.71 Bil Enterprise Value: 330.69 Bil PE Ratio: 0 PB Ratio: 4.29 GF Score: 83/100

Q1 2021 Glenmark Pharmaceuticals Ltd Earnings Call Transcript

Aug 17, 2020 / 03:00AM GMT
Release Date Price: ₹480.65 (+1.04%)
Operator

Ladies and gentlemen, good day, and welcome to the Q1 FY '21 Earning Conference Call of Glenmark Pharmaceuticals Limited.

(Operator Instructions) Please note that this conference is being recorded.

I would now like to hand the conference over to Mr. Jason D'souza. Thank you, and over to you, sir.

Jason D;souza
Glenmark Pharmaceuticals Limited - Senior VP & Head of Corporate Strategy

' -

Thank you, Janice. Apologies for the delay in the earnings call. We had a problem with the audio bridge. We'll begin Glenmark's Q1 Earnings Call.

Before we start the review of the operations for the quarter ended June 30, 2020. For the first quarter FY '21, Glenmark's consolidated revenue was at INR 23,447 million, recording an increase of 0.94%.

Business update on account of the COVID situation. The COVID-19 pandemic had a significant impact in India, as the entire country was under lockdown in April and most part of May. While the pharmaceutical plants being essential services were allowed to operate, it was challenging

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot